Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Johnson & Johnson
  6. News
  7. Summary
    JNJ   US4781601046

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00:02 2023-01-27 pm EST
168.23 USD   -0.39%
12:58pJohnson & Johnson's Janssen Says Carvykti Meets Target in Late-Stage Blood Cancer Trial
MT
08:53aJohnson & Johnson Unit Withdraws European Application for Imbruvica Drug Combination to Treat Mantle Cell Lymphoma
MT
01/26Sector Update: Healthcare Stocks Climb Back to Finish Higher
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson &Johnson CFO on Earnings Forecast, Costs, and Consumer Spinoff

01/24/2023 | 11:47am EST
share with twitter
share with LinkedIn
share with facebook

(MT Newswires) -- Johnson & Johnson CFO Joseph Wolk discusses the company's stronger-than-expected earnings forecast for 2023 and cost pressures with Guy Johnson and Alix Steel on "Bloomberg Markets."


© MT Newswires 2023
All news about JOHNSON & JOHNSON
12:58pJohnson & Johnson's Janssen Says Carvykti Meets Target in Late-Stage Blood Cancer Trial
MT
08:53aJohnson & Johnson Unit Withdraws European Application for Imbruvica Drug Combination to..
MT
01/26Sector Update: Healthcare Stocks Climb Back to Finish Higher
MT
01/26Sector Update: Health Care Stocks Advance Pre-Bell Thursday
MT
01/26Evotec, Johnson & Johnson's Janssen Biotech Enter Cancer Drug Development Collaboration
MT
01/26Evotec Shares Climb After Agreement With Janssen on Immunotherapies Development
DJ
01/26Evotec Starts Oncology-development Collaboration With Johnson & Johnson Unit
MT
01/25Johnson & Johnson : JNJ-USQ_Transcript_FINAL 2023-01-24
PU
01/25Morgan Stanley Adjusts Price Target on Johnson & Johnson to $180 From $176, Maintains E..
MT
01/25Atlantic Equities Adjusts Johnson & Johnson's Price Target to $168 From $160, Keeps Neu..
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 017 M - -
Net income 2022 20 668 M - -
Net cash 2022 10 806 M - -
P/E ratio 2022 21,3x
Yield 2022 2,61%
Capitalization 442 B 442 B -
EV / Sales 2022 4,53x
EV / Sales 2023 4,30x
Nbr of Employees 141 700
Free-Float 83,8%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 168,89 $
Average target price 181,45 $
Spread / Average Target 7,44%
EPS Revisions
Managers and Directors
Joaquin Duato Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
James D. Swanson Global Chief Information Officer & Executive VP
Dan Zelem Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-4.04%441 560
ELI LILLY AND COMPANY-4.40%330 671
NOVO NORDISK A/S0.14%309 711
ROCHE HOLDING AG-0.52%277 411
MERCK & CO., INC.-3.68%270 958
ABBVIE INC.-8.79%260 586